RecruitingPhase 2NCT07271186

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Studying Non-genetic systemic disease with glomerulopathy as a major feature

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Regeneron Pharmaceuticals
Principal Investigator
Clinical Trial Management
Regeneron Pharmaceuticals
Intervention
ALN-ANG3(drug)
Enrollment
270 enrolled
Eligibility
18-80 years · All sexes
Timeline
20262028

Study locations (29)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07271186 on ClinicalTrials.gov

Other trials for Non-genetic systemic disease with glomerulopathy as a major feature

Additional recruiting or active studies for the same condition.

See all trials for Non-genetic systemic disease with glomerulopathy as a major feature

← Back to all trials